The Daily Journal has named Goodwin partner Alexander Varond to its 2023 list of Top Healthcare Lawyers in California. This year’s winners were selected based on their market reputation, signature wins, and overall impact of their work in healthcare litigation, transactions, and counseling.
A partner in Goodwin’s Technology and Life Sciences groups and co-chair of the firm’s FDA Litigation practice, Varond advises on a wide range of cutting-edge FDA regulatory matters, with extensive experience in medical device and drug development, patent and exclusivity issues, and regulatory strategy. He also counsels on advertising and promotional issues, leads the FDA regulatory side of corporate transactions, and defends companies during civil and criminal investigations on matters such as off-label promotion and GMPs.
Daily Journal highlighted Varond’s role as lead company-side FDA regulatory counsel for Intellia Therapeutics, a leading clinical-stage genome editing company, in its $690 million underwritten public offering, and his work advising BELLUS Health Inc., a clinical-stage biopharmaceutical company, in its recent $153 million and $200 million public offerings.
Daily Journal also recognized Varond’s commitments outside of his practice. Splitting time between San Francisco and Washington, DC, he is a key contributor in driving the growth of the firm’s West Coast Life Sciences practice and other strategic areas. He serves as a board member of the Ogden CARES Foundation, a patient advocacy group dedicated to supporting families with Ogden syndrome, a life-threatening childhood neurodevelopmental condition. Varond is also a member of several industry groups including the Food and Drug Law Institute (FDLI) and the Drug Information Association, and he serves on a number of FDLI boards.
Among numerous other awards and honors, Varond has recently been named to Daily Journal’s Top 40 Under 40 List for 2022 and was recognized by The Best Lawyers in America for his work in FDA Law for 2022-2023. He has consistently been recognized in The Legal 500 United States for his work in Life Sciences and FDA Law, including being named a Next Generation Partner in Healthcare: Life Sciences for 2022-2023.